The Canadian journal of hospital pharmacy最新文献

Background: Patient care ratios for pharmacists are not well defined in Canada. A recent work-sampling study involving 6 medium and large hospitals within the region served by Lower Mainland Pharmacy Services, British Columbia, reported pharmacist-to-patient ratios of 1:13, 1:26, and 1:14 in internal medicine teaching units, hospitalist or internal medicine nonteaching units, and surgical units, respectively.

Objective: To determine the pharmacist-to-patient ratios required to provide comprehensive pharmaceutical care to adult patients admitted to medical and surgical units in medium and large hospitals in British Columbia.

Methods: In this cross-sectional electronic survey study, participants were asked to provide estimates of the time spent on and the frequency of 17 comprehensive pharmaceutical care tasks identified in the previous study, which was based on a Delphi method. The survey data were used to calculate pharmacy staffing ratios according to the World Health Organization workforce calculator.

Results: Fifty-eight pharmacists responded to the survey, of whom 41 (71%) were from medium and large hospitals. The optimal pharmacist-to-patient ratios were calculated as 1:7 for internal medicine teaching units; 1:10 for internal medicine nonteaching, hospitalist, and family practice units; and 1:14 for surgical units.

Conclusions: The pharmacist-to-patient ratios calculated in this study, using only pharmacists' self-reported information, were lower than those found previously. Further research is required to determine whether completion of every comprehensive care task is necessary, or if staffing ratios should reflect combinations of comprehensive care tasks based on patient complexity. National consensus guidelines on pharmacist staffing ratios may be valuable, given the current lack of standardization of pharmacy staffing ratios in hospitals.

Background: Sugammadex, a selective relaxant binding agent, works by encapsulating rocuronium or vecuronium to reverse neuromuscular blockade. It is an asset in emergencies requiring expedient reversal of neuromuscular blockade, such as situations involving difficult airways. A prevalent concern relating to sugammadex use is its higher cost compared with traditional reversal agents, contributing to more than 20% of operating room drug expenditures at Hamilton Health Sciences (Hamilton, Ontario) in 2019/20.

Objective: To use iterative Plan-Do-Study-Act cycles to reduce annual sugammadex expenditure at Hamilton Health Sciences by 50% from costs in the 2020/21 fiscal year.

Methods: Five Plan-Do-Study-Act cycles were implemented (January to April 2021) to increase awareness about the cost of sugammadex and appropriate indications for its use. The organization's Department of Pharmacy supplied data regarding acquisition of sugammadex before, during, and after the Plan-Do-Study-Act cycles, which were analyzed quantitatively. A data set regarding difficult airways at Hamilton Health Sciences was analyzed alongside the sugammadex data to aid in understanding the need for accessibility of this drug.

Results: Use of sugammadex in fiscal year 2021/22 at Hamilton Health Sciences decreased by 75% from the previous fiscal year, without compromising patient safety or drug availability. Analysis of the difficult airway data revealed that both anticipated and unanticipated cases of difficult airway were still prevalent across all hospitals, which highlights the importance of maintaining access to and knowledge of how to use sugammadex in the setting of difficult airways.

Conclusions: This cost-reduction project showed that user-based program designs can have a meaningful impact on resource utilization. Additionally, the difficult airway data set emphasized the clear need to maintain availability of and capabilities for administering sugammadex, given the prevalence of emergency airway situations.

Background: Opioids are known to induce delirium, and the incidence of delirium induced by individual opioids has been investigated. However, only a limited number of studies have examined the incidence of delirium induced by oral hydromorphone.

Objective: To investigate whether differences exist in the incidence of delirium associated with oral morphine and oral hydromorphone during the initiation phase of treatment.

Methods: The participants were opioid-naive inpatients with cancer who started oral morphine or oral hydromorphone at Shizuoka Cancer Center (in Shizuoka, Japan) between June 2017 and November 2020. The incidence of delirium in the first week of opioid use was compared between the 2 groups.

Results: A total of 90 patients met the inclusion criteria, 27 who received oral hydromorphone and 63 who received oral morphine. The incidence rate of delirium in the oral hydromorphone group tended to be higher (19%, 5/27) than in the oral morphine group (8%, 5/63), although the difference was not statistically significant (odds ratio 0.4, 95% confidence interval, 0.1-1.4, p = 0.16 by the Fisher exact test). Propensity score matching was used to control for differences in patient background as confounders in the development of delirium, following which the incidence rate of delirium remained higher, but not significantly so, in the oral hydromorphone group (11%, 2/19) than in the oral morphine group (5%, 1/19) (odds ratio 0.5, 95% confidence interval 0.04-5.7, p > 0.99 by the Fisher exact test).

Conclusions: There was no statistically significant difference in the incidence of delirium between those who received morphine and those who received hydromorphone, which suggests that for opioid-naive inpatients with cancer, oral hydromorphone can be used in a manner similar to that for oral morphine.

Background: Pregnant people, especially those with diabetes mellitus or hypertension, are particularly vulnerable to adverse drug reactions (ADRs).

Objective: To determine the incidence of and factors associated with ADRs in hospitalized pregnant people with diabetes and/or hypertension.

Methods: This prospective cohort study involved pregnant people with diabetes and/or hypertension admitted to a maternity hospital in Natal, Brazil, between August 2019 and July 2022. Data for various patient characteristics and the occurrence of ADRs were collected by means of interviewing patients and searching their medical charts. Multivariate logistic regression was used to identify and analyze the association of ADRs with various patient characteristics and other factors.

Results: A total of 571 pregnant people met the inclusion criteria. Over the study period, the incidence rate of ADRs was 634.4 (95% confidence interval [CI] 522.7-787.1) per 1000 patient-days, with 123 (21.5%) of the patients experiencing at least 1 incident. ADRs occurred predominately in the first 24 hours, with a marked decrease in frequency to the seventh day of admission. Methyldopa was identified as the cause in 42.1% (8/19) of cases of headache and 39.5% (17/43) of cases of sedation. Systemic corticosteroids were responsible for almost all cases of hyperglycemia (97.0% [32/33]). Blurred vision (82.4% [14/17]) and sedation (14.0% [6/43]) were related to the administration of antiemetics and antinauseants, especially scopolamine. Longer hospitalization time (OR 1.052, 95% CI 1.010-1.097, p = 0.016) and greater number of prescribed medications (OR 1.200, 95% CI 1.099-1.310, p < 0.001) were related to the occurrence of ADRs.

Conclusions: In this study, 1 of every 5 hospitalized pregnant people had at least 1 ADR, most often in the first 24 hours, with a decrease in incidence in the following days. Pregnant people with longer hospital stays and a greater number of medications had a higher risk of ADRs.